Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More
Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.
Related Articles
OCE Rare Cancers Program
Promoting development of new drug and biological products to treat patients with rare cancers
Collection Details : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis
Our findings suggest that NALIRIFOX and FOLFIRINOX should be the preferred options for patients who can tolerate these regimens, with gemcitabine plus nab-paclitaxel remaining a…
Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma
An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.
Initiating Prognostic Talk During Hospice Multidisciplinary Team Meetings: A Conversation Analytic Study – Andrea Bruun, Nicola White, Linda Oostendorp, Patrick Stone, Steven Bloch, 2024
Objective: Guidelines recommend that patients’ prognoses should be discussed by the palliative care multidisciplinary team. However, there is a lack of evidence…
Cannabis Linked to Structural and Functional Brain Differences in Older Adults – Oncology Nurse Advisor
Imaging studies demonstrate possible association between cannabis use and structural and functional deficits in the brain of older adult users.
New Therapies Expand Options in Recurrent Small Cell Lung Cancer
Ariel Lopez-Chavez, MD, discusses the current approach to managing recurrent small cell lung cancer especially in patients who have progressed after first-line chemotherapy.
Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer
Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.
Effect of Smoking Cessation Intervention on Survival After a Cancer Diagnosis
In a single-institution study reported in JAMA Oncology, Cinciripini et al explored the impact of quitting smoking after a smoking cessation intervention in patients following…
Peter Hall (@peterhall001.bsky.social)
Edinburgh based Oncologist and Researcher https://cancer-data.ecrc.ed.ac.uk/
